Affordable Access

Publisher Website

Is phosphoproteomics ready for clinical research?

Authors
Journal
Clinica Chimica Acta
0009-8981
Publisher
Elsevier
Volume
420
Identifiers
DOI: 10.1016/j.cca.2012.10.063
Keywords
  • Phosphoproteomics
  • Mass Spectrometry
  • Signaling
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Background For many diseases such as cancer where phosphorylation-dependent signaling is the foundation of disease onset and progression, single-gene testing and genomic profiling alone are not sufficient in providing most critical information. The reason for this is that in these activated pathways the signaling changes and drug resistance are often not directly correlated with changes in protein expression levels. In order to obtain the essential information needed to evaluate pathway activation or the effects of certain drugs and therapies on the molecular level, the analysis of changes in protein phosphorylation is critical. Methods Existing approaches do not differentiate clinical disease subtypes on the protein and signaling pathway level, and therefore hamper the predictive management of the disease and the selection of therapeutic targets. Conclusions The mini-review examines the impact of emerging systems biology tools and the possibility of applying phosphoproteomics to clinical research.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Are we ready for patient-based effect sizes in cli...

on Medical decision making : an i... 2005

When is a research procedure ready for clinical ap...

on Transplantation Proceedings June 1986

Get research-ready.

on Nursing management November 2002
More articles like this..